{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:35:16Z","timestamp":1763757316636,"version":"3.45.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008017","name":"Gustave Roussy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008017","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bulcan.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:29:50Z","timestamp":1759955390000},"page":"1385-1393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapy related myeloid neoplasm, same but different?"],"prefix":"10.1016","volume":"112","author":[{"given":"Lina","family":"El Murr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalil","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Willekens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Danu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Pilorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Auger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Saada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"De Botton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Micol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bulcan.2025.08.003_bib0110","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.bulcan.2023.02.022","article-title":"Therapy-related myelodysplastic syndromes in the genomics era","volume":"110","author":"Renneville","year":"2023","journal-title":"Bull Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2025.08.003_bib0115","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2643-3230.BCD-24-0103","article-title":"Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment","volume":"5","author":"Singhal","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.bulcan.2025.08.003_bib0120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41408-024-01140-5","article-title":"Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy","volume":"14","author":"Gross","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.bulcan.2025.08.003_bib0125","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2025.08.003_bib0130","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bulcan.2025.08.003_bib0135","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2025.08.003_bib0145","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.bulcan.2025.08.003_bib0150","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-22-1622","article-title":"Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience","volume":"28","author":"Marmouset","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.bulcan.2025.08.003_bib0155","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/s41409-023-02082-5","article-title":"Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC","volume":"58","author":"Rey","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2025.08.003_bib0160","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2017.01.024","article-title":"Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease","volume":"55","author":"Annereau","year":"2017","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.bulcan.2025.08.003_bib0165","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","article-title":"Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-na\u00efve patients with acute myeloid leukemia","volume":"15","author":"Willekens","year":"2022","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.bulcan.2025.08.003_bib0170","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2025.08.003_bib0175","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2025.08.003_bib0180","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1097\/HS9.0000000000000632","article-title":"Molecular landscape of therapy-related myeloid neoplasms in patients previously treated for gynecologic and breast cancers","volume":"5","author":"Khalife-Hachem","year":"2021","journal-title":"Hemasphere"},{"issue":"12","key":"10.1016\/j.bulcan.2025.08.003_bib0185","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41588-019-0525-5","article-title":"The mutational footprints of cancer therapies","volume":"51","author":"Pich","year":"2019","journal-title":"Nat Genet"},{"issue":"19","key":"10.1016\/j.bulcan.2025.08.003_bib0190","first-page":"2359","article-title":"Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures","volume":"141","author":"Diamond","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.08.003_bib0195","article-title":"Clonal hematopoiesis in patients with cancer: how much should we care?","volume":"7","author":"Renneville","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"20","key":"10.1016\/j.bulcan.2025.08.003_bib0200","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1200\/JCO.23.02547","article-title":"Clonal hematopoiesis and therapy-related myeloid neoplasms after autologous transplant for Hodgkin lymphoma","volume":"42","author":"Yan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2025.08.003_bib0205","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1158\/1078-0432.CCR-24-3683","article-title":"Clonal evolution of PPM1D mutations in the spectrum of myeloid disorders","volume":"31","author":"Fandrei","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.bulcan.2025.08.003_bib0210","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood.2022018236","article-title":"TP53mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype","volume":"141","author":"Hiwase","year":"2022","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125004394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125004394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:31:11Z","timestamp":1763757071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125004394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0007455125004394"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.08.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy related myeloid neoplasm, same but different?","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}